... as a second-line treatment option. [email protected] 2 12 2021 20 06 2022 31 8 2022 © 2022 The Author(s). Published by S. Karger AG, Basel 2022 Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0...

...: The median age was 68 (interquartile range 62–73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line...

... and October 2017 who experienced recurrence following cisplatin treatment (or carboplatin) plus pemetrexed or pemetrexed monotherapy as first-line treatment, and who underwent irinotecan plus gemcitabine combination therapy as second-line treatment. Irinotecan (60 mg/m 2 ) and gemcitabine (800 mg/m 2 ) were...

... investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty...

... results. While first-line treatment has been well established, there are no phase III trials supporting second-line treatment, and the phase II trials with chemotherapy do not show any clear benefit. In this study, we investigated the effect of adding bevacizumab to chemotherapy in second-line treatment...

... of mammalian target of rapamycin (mTOR), which are believed to inhibit tumour growth and tumour angiogenesis [ 19 ]. All of these targeted agents have shown significant efficacy in patients refractory to cytokine therapy [ 20,21,22,23,24,25,26 ], thus providing effective second-line treatment in this setting...

...E. Jäger; O. Klein; B. Wächter; B. Müller; U. Braun; A. Knuth Results with second-line treatment of advanced colorectal cancer are poor. Preliminary phase I/II results suggest encouraging response rates to high-dose 5-fluorouracil (FU) (2,600 mg/m 2 ) combined with folinic acid (FA) in pretreated...

... patient developed cardiomyopathy, another an acute myocardial infarction, and 3 patients had pathological changes on echocardiography or multigated nuclear angiography. Hematological and gastrointestinal toxicity was tolerable. We found MIX to be a potentially effective second-line treatment with mild...

...Sándor Eckhardt; Zoltán Hernádi; László Thurzó; A. Telekes; Bozena Sopkova; Zdenek Mechl; Marek Pawlicki; Sándor Kerpel-Fronius The objective of this trial was to define the antitumour activity and toxicity of etoposide for second-line treatment of patients with bulky ovarian carcinoma. Between...

...-line treatment for this type of tumor. Mitomycin-C Vinblastine Advanced breast cancer Second-line treatment © 1989 S. Karger AG, Basel 1989 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced...

.... Temozolomide Second-line treatment Non-small cell lung cancer Metronomic therapy The prognosis of patients with advanced non-small cell lung cancer (NSCLC) who fail or relapse after first-line treatment is particularly poor. However, a significant proportion of these patients are candidates...

...Edwin Herrmann; Stefan Bierer; Joachim Gerss; Thomas Köpke; Lothar Hertle; Christian Wülfing Objectives: It was the aim of this study to investigate the clinical differences between the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib as second-line treatment for cytokine-refractory kidney...

... as second-line treatment in patients with advanced pancreatic cancer. Patients and Methods: Twenty-six patients pretreated with gemcitabine-based chemotherapy were enrolled in the study. Docetaxel (75 mg/m 2 , i.v.) was administered every 3 weeks for a maximum of 6 cycles and gefitinib (250 mg/day, p.o...

..., instructions or products referred to in the content or advertisements. Weekly paclitaxel Non-small cell lung cancer Phase II trial Second-line treatment Systemic chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC) prolongs survival and palliates symptoms compared...

... with very mild toxicity. Because of the encouraging response rate in patients, whose disease progressed under the conventional intra-arterial therapy either with 5-FU/FA or 5-fluorodeoxyuridine, this regimen seems to be an effective second-line treatment and should be evaluated in nonpretreated patients...